Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sinemet in Oculocutaneous Albinism
NCT01663935Phase 2Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- Oct 2012
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of levodopa in Oculocutaneous albinism (OCA), sponsored by University of Wisconsin–Madison. Started Oct 2012; status: terminated.
02
Drugs
levodopa
03
Conditions
Oculocutaneous albinism (OCA)
Beyond the preview
Go deeper on NCT01663935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01663935.